<DOC>
	<DOC>NCT00451984</DOC>
	<brief_summary>The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.</brief_summary>
	<brief_title>Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Adults with stable antiretroviral therapy and negative for hepatitis A or B Prior hepatitis A or B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>interleukin-2</keyword>
	<keyword>vaccination</keyword>
	<keyword>treatment experienced</keyword>
</DOC>